Drugs.com - New Drug Approvals

FDA Approves Vykat XR (diazoxide choline) to Treat Hyperphagia in Prader-Willi Syndrome

REDWOOD CITY, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that the U.S. Food and Drug...

Mar 27, 2025 - 05:40
 0
FDA Approves Vykat XR (diazoxide choline) to Treat Hyperphagia in Prader-Willi Syndrome
REDWOOD CITY, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that the U.S. Food and Drug...
Read More

Tags:

Previous Article

Fastest-growing FT1000 company illuminates solar market evolution

Next Article

Brazil’s ‘Egg King’ shells out $1bn to acquire major US producer

Related Posts

Calquence Plus Chemoimmunotherapy Approved in the U.S. for Patients with Previously Untreated Mantle Cell Lymphoma

Calquence Plus Chemoimmunotherapy Approved in the U.S. ...

Feb 9, 2025  0

FDA Approves Tremfya (guselkumab) for Adult Patients with Moderately to Severely Active Crohn’s Disease

FDA Approves Tremfya (guselkumab) for Adult Patients wi...

Mar 24, 2025  0

Incyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of Niktimvo (axatilimab-csfr) 9 mg and 22 mg Vial Sizes

Incyte and Syndax Announce U.S. Food and Drug Administr...

Feb 9, 2025  0